Get started
Author

Craig L. Malmberg

Observed names: C. Malmberg, C.L. Malmberg, Craig Malmberg
Observed institution: National Marrow Donor Program
OpenAlex ID: A5111492011
Allogeneic Hematopoietic Cell Donor Selection: Contemporary Guidelines from the NMDP/CIBMTR
2025 · Antonio M. Jimenez Jimenez, Stephen R. Spellman, et al. · Transplantation and Cellular Therapy · 44
Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
2025 · Monzr M. Al Malki, Stephanie Bo-Subait, et al. · Journal of Clinical Oncology · 39
Frequencies and haplotype associations of non-expressed HLA alleles in ethnically diverse populations on the National Marrow Donor Program’s Be The Match Registry
2020 · Miranda Bauer, Jane Kempenich, et al. · Human Immunology · 9
Access: A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide for Patients with Hematologic Malignancies
2022 · Monzr M. Al Malki, Steven M Devine, et al. · Blood · 6
Post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis following mismatched unrelated donor peripheral blood stem cell (PBSC) transplantation.
2024 · Monzr M. Al Malki, Stephanie Bo-Subait, et al. · Journal of Clinical Oncology · 5
P008 Uncommon or unexpected DRB1-DRB3/4/5 associations in NMDP-BE the match recruitment donor population
2017 · Chelsey Kornetzke, Miranda Bauer, et al. · Human Immunology · 3
1-OR
2013 · Gail H. Flickinger, Susan Hsu, et al. · Human Immunology · 3
Post-Transplant Cyclophosphamide-Based Graft-Versus-host Disease Prophylaxis Following Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation Using Myeloablative Conditioning – Results from the Access Trial
2025 · Monzr M. Al Malki, Stephanie Bo-Subait, et al. · Transplantation and Cellular Therapy · 2
Mismatching of unrelated donors beyond a single HLA-locus does not adversely impact outcomes at one year following transplantation: Results from the NMDP sponsored ACCESS study
2025 · Monzr M. Al Malki, Stephanie Bo-Subait, et al. · Blood · 1
PDF
Erratum: Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
2026 · Monzr M. Al Malki, Stephanie Bo-Subait, et al. · Journal of Clinical Oncology
Phase II Study of Posttransplant Cyclophosphamide‐Based Graft‐Versus‐Host Disease Prophylaxis After HLA ‐Mismatched Unrelated Donor Reduced Intensity Transplantation: Results From the ACCESS Trial Expansion Cohort
2026 · Brian C. Shaffer, Monzr M. Al Malki, et al. · American Journal of Hematology
PDF
Outcomes after 7/8 and <7/8 mismatched unrelated donor PBSC transplantation with PTCy: results from the ACCESS trial
2026 · Antonio Martin Jimenez Jimenez, Joseph Stanek, et al. · Blood Advances
Expanding Donor Access: Comparable One Year Outcomes in 4–6/8 and 7/8 Mismatched Unrelated Donor Transplantation with Ptcy-Based GVHD Prophylaxis (ACCESS Trial)
2026 · Monzr M. Al Malki, Stephanie Bo-Subait, et al. · Transplantation and Cellular Therapy
Phase II Study of post transplant cyclophosphamide-based graft versus host disease prophylaxis after HLA-mismatched unrelated donor transplantation and reduced intensity conditioning: Results from the NMDP-sponsored access expansion Study
2025 · Mahasweta Gooptu, Monzr M. Al Malki, et al. · Blood
PDF
An Integrated Evidence-Based Solution for Unrelated Donor Selection Support: The NMDP Model
2025 · William Grose, Medhat Askar, et al. · Transplantation and Cellular Therapy
Addressing Ethnically Diverse Patient Representation in Hematopoietic Cell Transplant Clinical Trials: Insights Gained through the Access Trial
2025 · Dr. Jeffery J. Auletta, Stephanie Bo-Subait, et al. · Transplantation and Cellular Therapy
HCT Donor Options for Patients without Matched Donors- Impact of Patient HLA and Genetic Ancestry in the NMDP-Sponsored, CIBMTR-Led Access Trial
2025 · Dr. Abeer Madbouly, Martin Maiers, et al. · Transplantation and Cellular Therapy
Patient-Donor Matching Models for Hematopoietic Cell Transplantation in the United States
2025 · Yung-Tsi Bolon, Abu Sayed Chowdhury, et al. · Transplantation and Cellular Therapy
Trial in Progress: Cureaa - a Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia, Blood and Marrow Transplant Clinical Trials Network (BMT CTN) #2207
2024 · Akshay Sharma, Abhishek A. Mangaonkar, et al. · Blood
PDF
Addressing Patient Representation in Hematopoietic Cell Transplant Clinical Trials: Insights Gained through the Access Trial
2024 · Jeffery J. Auletta, Stephanie Bo-Subait, et al. · Blood
PDF
O39 Characterization of HLA expression on memory-like (ML) NK cells
2023 · M. Maiers, C. Malmberg, et al. · Human Immunology
Access: A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide for Patients with Hematologic Malignancies
2023 · Monzr M. Al Malki, Brian C. Shaffer, et al. · Transplantation and Cellular Therapy
P035 A method for large-scale analysis of HLA genetic variation
2016 · Wei Wang, Yung-Tsi Bolon, et al. · Human Immunology
P065 Information theory-based analysis of classical HLA genes
2016 · Hu Huang, Wei Wang, et al. · Human Immunology
Frequency of Class I common or well documented null alleles in National Marrow Donor Program high resolution typing programs
2015 · Jessica Henry, Jane Kempenich, et al. · Human Immunology
Works count: 29
Citation count: 112
H-index: 5
I10-index: 2
Year
Topic
Type